Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Shares of TRVN opened at $1.99 on Friday. The company has a 50 day moving average price of $3.77 and a 200-day moving average price of $6.41. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $19.23. The stock has a market capitalization of $36.50 million, a PE ratio of -0.74 and a beta of 1.02.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($9.25) by $9.02. The business had revenue of $0.33 million during the quarter. Equities research analysts forecast that Trevena will post -32.25 EPS for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.